- cafead   May 12, 2023 at 10:22: AM
via New data from the Phase IIIb HARMONIE trial showed Sanofi’s and AstraZeneca’s respiratory syncytial virus antibody candidate nirsevimab exerts a strong protective effect in infants under 12 months, the companies announced Friday.
article source
article source